Xeris Biopharma
Xeris Biopharma is a Chicago-based, NASDAQ-listed specialty biopharmaceutical company that develops and commercializes proprietary ready-to-use injectable therapies in endocrinology and rare diseases, anchored by Gvoke, Recorlev, and Keveyis, leveraging its XeriSol and XeriJect non-aqueous formulation platforms.
- Company typePublic
- Founded2005
- HeadquartersChicago, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Xeris Biopharma does
Xeris Biopharma Holdings, Inc. is a Chicago-based, NASDAQ-listed (XERS) specialty biopharmaceutical company that develops and commercializes injectable therapies in endocrinology, neurology, and gastroenterology. Its portfolio is anchored by three FDA-approved products: Gvoke HypoPen (a premixed, ready-to-use glucagon autoinjector for severe hypoglycemia), Recorlev (levoketoconazole for endogenous Cushing's syndrome), and Keveyis (dichlorphenamide, the first FDA-approved treatment for primary periodic paralysis). Gvoke VialDx, partnered with American Regent, extends the glucagon franchise into diagnostic radiology. All commercial products are enabled by two proprietary non-aqueous formulation platforms — XeriSol, which produces room-temperature-stable small-molecule and peptide solutions, and XeriJect, which produces ultra-concentrated (>450 mg/mL) non-settling suspensions of biologics — that eliminate reconstitution and cold-chain handling.
The company operates a specialty pharmaceutical business model: products are prescription-only, priced via negotiated rates with payers/PBMs, and distributed through specialty pharmacy networks and hospital/institutional channels. Xeris engages healthcare professionals via a dedicated field sales force, medical affairs programs, and patient support (XerisCareConnection), targeting endocrinologists, primary care physicians, and hospitals. Revenue grew from $203M in 2024 to $292M in 2025 (+43.7% YoY), with Recorlev as the primary growth engine at approximately 95% YoY; the company reached full-year profitability in 2025 at 86% gross margin and guided FY2026 to $375–390M. The pipeline is led by XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine for hypothyroidism, supported by patent estates extending protection on commercial assets through 2039–2040 and orphan exclusivity for Recorlev through December 2028.
Xeris Biopharma firmographics
Firmographics- Name
- Xeris Biopharma
- Legal name
- Xeris Pharmaceuticals, Inc.
- Website
- https://xerispharma.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Xeris Biopharma is a Chicago-based, NASDAQ-listed specialty biopharmaceutical company that develops and commercializes proprietary ready-to-use injectable therapies in endocrinology and rare diseases, anchored by Gvoke, Recorlev, and Keveyis, leveraging its XeriSol and XeriJect non-aqueous formulation platforms.
- Ownership category
- akta.pro rank
Xeris Biopharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
- akta.pro secondary industry
- Glucagon Rescue Delivery Devices (Auto-Injectors, Nasal) (HLAHAHAK)
Keywords
Where Xeris Biopharma is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Xeris Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Others
Revenue model
- Product Sales - Recorlev: Recorlev (levoketoconazole) for treatment of endogenous hypercortisolemia in Cushing's syndrome. Net revenue of $139 million in 2025, $49.8 million in Q1 2026, growing approximately 95% year-over-year. Primary revenue driver with peak sales target of $1 billion by 2035.
- Product Sales - Gvoke: Gvoke (glucagon injection) for severe hypoglycemia in diabetes patients. First FDA-approved premixed ready-to-use glucagon in autoinjector form. Revenue remained relatively flat due to Medicare coverage challenges.
- Product Sales - Keveyis: Keveyis (dichlorphenamide) for primary periodic paralysis. First FDA-approved treatment for this rare disease. Revenue grew approximately 4% year-over-year.
- Gvoke VialDx Partnership: Partnership with American Regent for Gvoke VialDx (glucagon injection) for gastrointestinal motility inhibition during radiologic examinations.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Xeris Biopharma product offering
Product offeringCore offering
Xeris Biopharma develops, manufactures, and commercializes ready-to-use injectable specialty pharmaceutical products for patients with endocrinology, neurology, and gastroenterology conditions. Its commercial portfolio centers on Gvoke HypoPen (premixed glucagon for severe hypoglycemia), Recorlev (levoketoconazole for endogenous Cushing's syndrome), Keveyis (dichlorphenamide for primary periodic paralysis), and Gvoke VialDx (glucagon for GI diagnostic procedures), built on the proprietary XeriSol and XeriJect non-aqueous formulation platforms.
Product overview
Xeris Biopharma is a growth-oriented biopharmaceutical company with three FDA-approved commercial products and a pipeline of development programs. The core portfolio consists of Gvoke HypoPen (ready-to-use glucagon for severe hypoglycemia), Recorlev (cortisol synthesis inhibitor for Cushing's syndrome), and Keveyis (treatment for primary periodic paralysis). The company also commercializes Gvoke VialDx for gastrointestinal diagnostic procedures. The pipeline is led by XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine for hypothyroidism. Xeris leverages two proprietary technology platforms—XeriSol for small molecules/peptides and XeriJect for biologics—to develop ready-to-use, room-temperature stable injectable formulations.
Differentiator
Problem solved
Functional benefit
Brands
- Gvoke: Ready-to-use liquid glucagon injection for severe hypoglycemia in adults and pediatric patients age 2 years and older with diabetes. Includes Gvoke HypoPen (autoinjector) and Gvoke VialDx (diagnostic aid).
- Recorlev
- Keveyis
- XeriSol
- XeriJect
- Xeris CareConnection
Products and services
- Gvoke HypoPen Premixed, ready-to-use glucagon autoinjector for the treatment of severe hypoglycemia in adult and pediatric patients aged 2 years and older with diabetes; available in pediatric (0.5mg/0.1mL) and adult (1.0mg/0.2mL) doses.
- Recorlev Oral cortisol synthesis inhibitor (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative.
- Keveyis Oral carbonic anhydrase inhibitor (dichlorphenamide) and the first FDA-approved treatment for primary periodic paralysis, including primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
- Gvoke VialDx Ready-to-use glucagon injection for intravenous use as a diagnostic aid during radiologic examinations, temporarily inhibiting movement of the gastrointestinal tract in adult patients; partnered with American Regent for U.S. commercialization.
- XP-8121 Once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism; Phase 3-ready; supported by a USPTO Notice of Allowance on its patent application.
Quantifiable outcome
- Revenue growth of 43.7% to $292 million in 2025
- +3 more outcomes
Companies that use Xeris Biopharma
Customer profileSegments4 records
Ideal customer profiles3 records
Xeris Biopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Xeris Biopharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- American RegentcorePartnership for U.S. launch of Gvoke VialDx (glucagon injection) as a gastrointestinal motility inhibitor for radiologic examinations. FDA approved product with partnered commercialization.
- ReAlta Life SciencesminorJonathan Rigby, appointed to ReAlta Life Sciences board, is a biotech veteran with experience leading acquisitions including approximately $350 million acquisition of Trevyent by United Therapeutics. Connection through Xeris executive network.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Xeris Biopharma competitors and assessment
Company assessmentRegional players
- Ferring Pharmaceuticals: Private, Switzerland-headquartered specialty pharma with strengths in reproductive endocrinology, gastroenterology, and rare diseases. Comparable therapeutic-area mix, though primarily operating outside the US where Xeris is concentrated.
Direct peers
- ANI Pharmaceuticals: Specialty pharmaceutical company focused on niche and rare-disease therapeutics, often acquired via corporate carve-outs. Comparable commercial model (rare-disease, specialty sales force) and recent growth-via-acquisition playbook.
- Zealand Pharma: Peptide therapeutics company with a glucagon franchise (e.g., dasiglucagon) for hypoglycemia and a pipeline of peptide-based endocrine therapies, directly comparable to Xeris on peptide injectable technology and endocrinology focus.
- MannKind Corporation: Specialty pharma built around novel drug-delivery technology platforms (Technosphere for inhaled products such as Afrezza, and endocrine focus via insulin/glucagon programs). Closely analogous model of platform-enabled injectable/endocrinology drug delivery.
- Corcept Therapeutics: Specialty pharma focused on cortisol modulation and the leading developer of a competing Cushing's syndrome therapy (Relacorilant, currently subject to an FDA Complete Response Letter). Direct overlap in endocrine/rare-disease go-to-market and prescriber base.
Broad incumbents
- Endo International: Diversified specialty pharmaceutical company with established specialty injectable and endocrine product portfolios. Comparable broader portfolio of injectable specialty drugs even though much larger in scale.
- Amphastar Pharmaceuticals: Established specialty injectable pharmaceutical manufacturer with a portfolio of hard-to-formulate injectable products including glucagon and other complex generics. Comparable on injectables formulation expertise and endocrinology exposure.
- Supernus Pharmaceuticals: Mid-sized specialty pharma with central nervous system and endocrine-related commercial assets, scaled via product acquisitions. Comparable in size, specialty pharma channels, and growth orientation.
- Madrigal Pharmaceuticals: Endocrinology-focused specialty pharma (metabolic liver disease with resmetirom). Similar therapeutic-area profile in endocrinology and a comparable size and capitalization tier.
Others
- Hovione: Specialty contract drug development and manufacturing organization with strong capabilities in particle engineering and complex injectable formulations. Relevant as a potential partner/competitor in formulation technology rather than as a commercial endocrinology competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Xeris Biopharma social profiles
Digital presenceXeris Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xeris Biopharma leadership team
Management profileNumber of profiles
Profiles8 records
Xeris Biopharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Xeris Biopharma funding detail
Funding detailFunding overview
Funding rounds15 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xeris Biopharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xeris Biopharma
What does Xeris Biopharma do?
Xeris Biopharma develops, manufactures, and commercializes ready-to-use injectable specialty pharmaceutical products for patients with endocrinology, neurology, and gastroenterology conditions. Its commercial portfolio centers on Gvoke HypoPen (premixed glucagon for severe hypoglycemia), Recorlev (levoketoconazole for endogenous Cushing's syndrome), Keveyis (dichlorphenamide for primary periodic paralysis), and Gvoke VialDx (glucagon for GI diagnostic procedures), built on the proprietary XeriSol and XeriJect non-aqueous formulation platforms.
Is Xeris Biopharma a public or private company?
Xeris Biopharma is a public company. It is classified as public and is currently operating.
When was Xeris Biopharma founded?
Xeris Biopharma was founded in 2005. It employs 251 to 500 people.
Where is Xeris Biopharma based?
Xeris Biopharma is headquartered in Chicago, United States, in the North America region.
How does Xeris Biopharma make money?
Four revenue lines are on record. Product Sales - Recorlev is the primary driver. The others are product Sales - Gvoke, product Sales - Keveyis and gvoke VialDx Partnership.
Who are Xeris Biopharma's main competitors?
Ferring Pharmaceuticals is listed as a regional player. Direct peers are ANI Pharmaceuticals, Zealand Pharma, MannKind Corporation and Corcept Therapeutics. Broad incumbents are Endo International, Amphastar Pharmaceuticals, Supernus Pharmaceuticals and Madrigal Pharmaceuticals. Hovione is listed as an others.
Does Xeris Biopharma have an API?
No public API is recorded for Xeris Biopharma.
What industry is Xeris Biopharma in?
Xeris Biopharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAHAHAK, Glucagon Rescue Delivery Devices (Auto-Injectors, Nasal). Its NAICS code is 325414 and its SIC code is 2834.